FDG-PET in the detection of bone marrow disease in Hodgkin's disease and aggressive non-Hodgkin's lymphoma and its impact on clinical management

Quarterly Journal of Nuclear Medicine and Molecular Imaging

Volumn 52, Issue 1, 2008, Pages 9-16

  Pelosi, E ^a,b   Penna, D ^a   Deandreis, D ^a   Chiappella, A ^a   Skanjeti, A ^a   Vitolo, U ^a   Bisi, G ^a   Corrao, S ^c  

^a MOLINETTE HOSPITAL   (Italy)

^b IRMET SpA   (Italy)

^c Giovanni Battista Hospital ^*  (Italy)

Author keywords

Biopsy; Bone marrow diseases; Fludeoxyglucose, F18; Hodgkin disease; Lymphoma; Lymphoma, non Hodgkin; Tomography, emission computed

Indexed keywords

ANTINEOPLASTIC AGENT; FLUORODEOXYGLUCOSE F 18;

ADOLESCENT; ADULT; AGED; ARTICLE; BONE MARROW BIOPSY; BONE MARROW DISEASE; CANCER CLASSIFICATION; CANCER STAGING; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCEMENT; CONTROLLED STUDY; CORRELATION ANALYSIS; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST; DIAGNOSTIC VALUE; FEMALE; HISTOPATHOLOGY; HODGKIN DISEASE; HUMAN; HUMAN TISSUE; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; NONHODGKIN LYMPHOMA; POSITRON EMISSION TOMOGRAPHY; PREDICTION; SCHOOL CHILD; SENSITIVITY AND SPECIFICITY; TREATMENT PLANNING; WHOLE BODY CT; WHOLE BODY PET;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BIOPSY, NEEDLE; BONE MARROW; BONE MARROW NEOPLASMS; CHILD; FEMALE; FLUORODEOXYGLUCOSE F18; HODGKIN DISEASE; HUMANS; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY; PREDICTIVE VALUE OF TESTS; RADIOPHARMACEUTICALS; SENSITIVITY AND SPECIFICITY;

EID: 40449087684     PISSN: 18244785     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (58)

1. Jost LM, Stahel RA; ESMO Guidelines Task Force. ESMO Minimum Clinical Recommendations for diagnosis, treatment and follow-up of Hodgkin's disease. Ann Oncol 2005;(16 Suppl 1):i54-5.
2. Hiddemann W, Dreyling M, Stahel RA; ESMO Guidelines Task Force. Minimum Clinical Recommendations for diagnosis, treatment and follow-up of newly diagnosed follicular lymphoma. Ann Oncol 2005;(16 Suppl 1):i56-7.
3. Jost LM, Stahel RA; ESMO Guidelines Task Force. ESMO Minimum Clinical Recommendations for diagnosis, treatment and follow-up of relapsed large cell non-Hodgkin's lymphoma. Ann Oncol 2005;(16 Suppl 1):i60-1.
4. Ng AK, Bernardo MV, Weller E, Backstrand K, Silver B, Marcus KC et al. Second malignancy after Hodgkin disease treated With radiation therapy with or without chemotherapy: long-term risks and risk factors. Blood 2002;100:1989-96.
5. Edeiken-Monroe B, Edeiken J, Kim EE. Radiologic concepts of lymphoma of bone. Radiol Clin North Am 1990;28:841-64.
6. Guermazi A, Brice P, cle Kerviler EE, Ferme C, Hennequin C, Meignin V et al. Extranodal Hodgkin disease: spectrum of disease. Radiographics 2001;21:161-79.
7. Carbone PP, Kaplan HS, Musshoff K, Smithers DW, Tubiana M. Report of the Committee on Hodgkin's Disease Staging Classification. Cancer Res 1971;31:1860-1.
8. Ponzoni M, Ciceri F, Crocchiolo R, Famoso G, Doglioni C. isolated bone marrow occurrence of classic Hodgkin's lymphoma in an HIV-negative patient. Haematologica 2006;91:ECRO4.
9. Levis A, Pietrasanta D, Godio L, Vitolo U, Ciravegna G, Di Vito et al. A large-scale study of bone marrow involvement in patients with Hodgkin's lymphoma. Clin Lymphoma 2004;5:50-5.
10. Gronich N, Radnay J, Shapiro H, Manor Y, Lahav M, Lishner M. Clinical outcome of low-grade NHL patients with bone marrow involvement. Eur J Clin Invest 2007;37:305-9.
11. Bremnes RM, Bremnes Y, Donnem T. High-grade non-Hodgkin's lymphoma treated in northern Norway - treatment, outcome, and prognostic factors. Acta Oncol 1999;38:117-24.
12. Conlan MG, Bast M, Armitage JO, Weisenburger DD. Bone marrow involvement by non-Hodgkin's lymphoma: the clinical significance of morphologic discordance between the lymph node and bone marrow. Nebraska Lymphoma Study Group. J Clin Oncol 1990;8:1163-72.
13. Morra E, Lazzarino, M, Castello A, Inverardi D, Coci A, Pagnucco G et al. Bone marrow and blood involvement by non-Hodgkin's lymphoma: a study of clinicopathologic correlations and prognostic significance in relationship to the Working Formulation. Eur J Haematol 1989;42:445-53.
14. Vogler JB 3rd, Murphy WA. Bone marrow imaging. Radiology 1988; 168:679-93.
15. Franco V, Tripodo C, Rizzo A, Stella M, Florena AM. Bone marrow biopsy in Hodgkin's lymphoma. Eur J Haematol 2004;73:149-55.
16. Gossmann A, Eich HT, Engert A, Josting A, Muller RP, Diehl V et al. CT and MR imaging in Hodgkin's disease; present and future. Eur J Haematol Suppl 2005;66:83-9.
17. Hoane BR, Shields AF, Porter BA, Shulman HM. Detection of lymphomatous bone marrow involvement with magnetic resonance imaging. Blood 1991;78:728-38.
18. Brennan DD, Gleeson T, Coate LE, Cronin C, Carney D, Eustace SJ. A comparison of whole-body MRI and CT for the staging of lymphoma. Am J Roentgenol 2005; 185:711-6.
19. Brunning RD, Bloomfield CD, McKenna RW, Peterson LA. Bilateral trephine bone marrow biopsies in lymphoma and other neoplastic diseases. Ann Intern Med 1975;82:365-6.
20. Coller BS, Chabner BA, Gralnick HR. Frequencies and patterns of bone marrow involvement in non-Hodgkin lymphomas: observations on the value of bilateral biopsies. Am J Hematol 1977;3:105-19.
21. Moog F, Bangerter M, Kotzerke J, Guhlmann A, Frickhofen N, Reske SN. 18-F-fluorodeoxyglucose-positron emission tomography as a new approach to detect lymphomatous bone marrow. J Clin Oncol 1998;16:603-9.
22. Moog F, Kotzerke J, Reske SN. FDG PET can replace bone scintigraphy in primary staging of malignant lymphoma. J Nucl Med 1999;40:1407-13.
23. Even-Sapir E. Imaging of malignant bone involvement by morphologic scintigraphic, and hybrid modalities. J Nucl Med 2005;46:1356-67.
24. Elstrom R, Guan L, Baker G, Nakhoda K, Vergilio JA, Zhuang H et al. Utility of FDG-PET scanning in lymphoma by WHO classification. Blood 2003;101:3875-6.
25. 18F-FDG PET for evaluation of bone marrow infiltration in staging of lymphoma: a metaanalysis. J Nucl Med 2005;46:958-63.
26. Cheson BD, Pfistner B, Juweid ME, Gascoyne RD, Specht L, Horning SJ et al. Revised response criteria for malignant lymphoma. J Clin Oncol 2007;25:579-86.
27. Juweid ME, Stroobants S, Hoekstra OS, Mottaghy FM, Dietlein M, Guermazi A et al. Use of positron emission tomography for response assessment of lymphoma: consensus of the imaging Subcommittee of International Harmonization Project in Lymphoma. J Clin Oncol 2007;25:571-8.
28. Kirby AM, Mikhaeel NG. The role of FDG PET in the management of lymphoma: what is the evidence base? Nucl Med Commun 2007;28:335-54.
29. Stumpe KM, Urbinelli M, Steinert HC, Glanzmann C, Buck A, von Schulthess GK. Whole-body positron emission tomography using fluorodeoxyglucose for staging of lymphoma: effectiveness and comparison with computed tomography. Eur J Nucl Med 1998;25:721-8.
30. Buchmann I, Reske SN. Novel imaging techniques in NHL: clinical results with PET imaging. Ann Hematol 2001;(80 Suppl 3):B54-7.
31. Jhanwar YS, Straus DJ. The role of PET in lymphoma. J Nucl Med 2006 47:1326-34.
32. Naumann R, Beuthien-Baumann B, Reiss A, Schulze J, Hanel A, Bredow J et al. Substantial impact of FDG PET imaging on the therapy decision in patients with early-stage Hodgkin's lymphoma. Br J Cancer 2004;90:620-5.
33. Hoskin PJ. PET in lymphoma: what are the oncologist's needs? Eur J Nucl Med Mol Imaging 2003;30 Suppl 1:S37-41.
34. Carr R, Barrington SF, Madan B O'Doherty MJ, Saunders CA, van der Watt J et al. Detection of lymphoma in bone marrow by whole-body positron emission tomography. Blood 1998;91:3340-6.
35. 18F]fluorodeoxyglucose positron emission tomography imaging complement biopsy results from the iliac crest for the detection of bone marrow involvement in patients with malignant lymphoma? Nucl Med Commun 2006;27:11-5.
36. Schaefer NG, Strobel K, Taverna C, Harry TF. Bone involvement in patients with lymphoma: the role of FDG-PET/CT. Eur J Nucl Med Mol Imaging 2007;34:60-7.
37. Buchmann I, Reinhardt M, Eisner K, Bunjes D, Altehoefer C, Finke J et al. 2-(fluorine-18)fluoro-2-deoxyglucose positron emission tomography in the detection and staging of malignant lymphoma. A bicenter trial. Cancer 2001;91:889-99.
38. Sasaki M, Kuwabara Y, Koga H, Nakagawa M, Chen T, Kaneko K et al. Clinical impact of whole body FDG-PET on the staging and therapeutic decision making for malignant lymphoma. Ann Nucl Med 2002;16:337-45.
39. 67Ga scan. Yonsei Med J 2003;44:779-86.
40. Partridge S, Timothy A, O'Doherty MJ, Hain SF, Rankin S, Mikhaeel G. 2-fluorine-18-fluoro-2-deoxy-D-glucose positron emission tomography in the pre-treatment staging of Hodgkin lymphoma: influence on patient management in a single institution. Ann Oncol 2000;11:1273-9.
41. 18F-fluorodeoxyglucose compared to standard procedures for staging patients with Hodgkin lymphoma. Haematologica 2001;86:266-73.
42. 18F-FDG) for the staging of low-grade non-Hodgkin's lymphoma (NHL). Ann Oncol 2001;12:825-30.
43. Elstrom R, Guan L, Baker G, Nakhoda K, Vergilio J, Zhuang H et al. Utility of FDG-PET scanning in lymphoma by WHO classification. Blood 2003;101:3875-6.
44. 18F-FDG-PET) for staging and follow-up of marginal zone B-cell lymphoma. Oncology 2003;64:336-40.
45. 18F]FDG in childhood lymphoma: clinical utility and impact on management. Eur J Nucl Med Mol Imaging 2002; 29:1155-65.
46. Wirth A, Seymour JF, Hicks RJ, Ware R, Fisher R, Prince M et al. Fluorine-18 fluorodeoxyglucose positron emission tomography, gallium-67 scintigraphy, and conventional staging for Hodgkin lymphoma and non-Hodgkin's lymphoma. Am J Med 2002;112:262-8.
47. Chiang SB, Rebenstock A, Guan L, Alavi A, Zhuang H. Diffuse bone marrow involvement of Hodgkin lymphoma mimics hematopoietic cytokine-mediated FDG uptake on FDG PET imaging. Clin Nucl Med 2003;28:674-6.
48. 18FDG-PET and PET/CT oncologic imaging. Semin Nucl Med 2004; 34:122-33.
49. Yao WJ, Hoh CK, Hawkins RA, Glaspy JA, Weil JA, Lee SJ et al. Quantitative PET imaging of bone marrow glucose metabolic response to hematopoietic cytokines. J Nucl Med 1995;36:794-9.
50. Knopp MV, Bischoff H, Rimac A, Oberdorfer F, van Kaick G. Bone marrow uptake of fluorine-18-fluorodeoxyglucose following treatment with hematopoietic growth factors: initial evaluation. Nucl Med Biol 1996;23:845-9.
51. Sugawara Y, Fisher SJ, Zasadny KR, Kison PV, Baker LH, Wahl RL. Preclinical and clinical studies of bone marrow uptake of fluorine-1-fluorodeoxyglucose with or without granulocyte colony-stimulating factor during chemotherapy. J Clin Oncol 1998;16:173-80.
52. Hollinger EF, Alibazoglu H, Ali A, Green A, Lamonica G. Hematopoietic cytokine-mediated FDG uptake simulates the appearance of diffuse metastatic disease on whole-body PET imaging. Clin Nucl Med 1998;23:93-8.
53. Chhabra A, BaLra K, Makler PT Jr. Obscured bone metastases after administration of hematopoietic factor on FDG-PET. Clin Nucl Med 2006;31:328-30.
54. Kazama T, Swanston N, Podoloff DA, Macapinlac HA Effect of colony-stimulating factor and conventional- or high-dose chemotherapy on FDG uptake in bone marrow. Eur J Nucl Med Mol Imaging 2005;32:1406-11.
55. Blodgett TM, Ames JT, Torok FS, McCook BM, Meltzer CC. Diffuse bone marrow uptake on whole-body F-18 fluorodeoxyglucose positron emission tomography in a patient taking recombinant erythropoietin. Clin Nucl Med 2004;29:161-3.
56. Aflalo-Hazan V, Gutman F, Kerrou K, Montravers F, Grahek D, Talbot JN. Increased FDG uptake by bone marrow in major betathalassemia. Clin Nucl Med 2005;30:754-5.
57. 18F-FDG uptake by bone marrow and hematological parameters: measurements by PET/CT. Nucl Med Biol 2006; 33:999-1004.
58. Metser U, Even-Sapir E. Increased (18)F-fluorodeoxyglucose uptake in benign, nonphysiologic lesions found on whole-body positron emission tomography/computed tomography (PET/CT): accumulated data from four years of experience with PET/CT. Semin Nucl Med 2007;37:206-22.